Meritage Pharma is committed to the development of prescription products based on proven safe and effective molecules to meet the unmet needs of patients and their caregivers. Meritage Pharma’s initial product candidate is intended for the treatment of allergic inflammation of the gastrointestinal tract.
Meritage Pharma’s management team has an established track record of building specialty pharmaceutical companies, and in identifying and developing novel products for the treatment of atopic conditions. Meritage Pharma was founded in March 2008 and has raised $22.5M in Series A financing from Domain Associates, Latterell Venture Partners and The Vertical Group.
|03/01/08||Series A||22.5M||Domain Associates, Latterell Venture Partners, the Vertical Group||Unknown|